Ying K Tam
Overview
Explore the profile of Ying K Tam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
7244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papp T, Zeng J, Shahnawaz H, Akyianu A, Breda L, Yadegari A, et al.
Mol Ther
. 2025 Mar;
PMID: 40087866
mRNA-based therapeutics delivered via lipid nanoparticles (LNP-mRNA) hold great promise for treating diverse diseases. However, further improvements are needed to refine outcomes in non-vaccine, extrahepatic applications, such as minimizing the...
2.
Connors J, Joyner D, Mege N, Cusimano G, Bell M, Marcy J, et al.
Commun Biol
. 2025 Feb;
8(1):285.
PMID: 39987408
No abstract available.
3.
Castruccio Castracani C, Breda L, Papp T, Guerra A, Radaelli E, Assenmacher C, et al.
Blood
. 2024 Dec;
145(1):98-113.
PMID: 39656107
X-linked sideroblastic anemia (XLSA) is a congenital anemia caused by mutations in ALAS2, a gene responsible for heme synthesis. Treatments are limited to pyridoxine supplements and blood transfusions, offering no...
4.
Abt E, Lam A, Noguchi M, Rashid K, McLaughlin J, Teng P, et al.
Proc Natl Acad Sci U S A
. 2024 Nov;
121(49):e2406332121.
PMID: 39589869
Combining a T cell-targeting mRNA vaccine encoding the conserved SARS-CoV-2 RNA-dependent RNA polymerase, RdRp, with a Spike-encoding mRNA vaccine may offer an additional pathway toward COVID-19 protection. Here, we show...
5.
Atochina-Vasserman E, Lindesmith L, Mirabelli C, Ona N, Reagan E, Brewer-Jensen P, et al.
NPJ Vaccines
. 2024 Oct;
9(1):182.
PMID: 39353926
Nucleoside-modified mRNA-LNP vaccines have revolutionized vaccine development against infectious pathogens due to their ability to elicit potent humoral and cellular immune responses. In this article, we present the results of...
6.
Kafle S, Montoya B, Tang L, Tam Y, Muramatsu H, Pardi N, et al.
Mol Ther Nucleic Acids
. 2024 Aug;
35(3):102279.
PMID: 39188304
The role of CD4 T cells in the induction of protective CD8 T cells by mRNA lipid nanoparticle (LNP) vaccines is unknown. We used B6 or mice depleted or not...
7.
Hendricks G, Grigoryan L, Navarro M, Catanzaro N, Hubbard M, Powers J, et al.
bioRxiv
. 2024 Aug;
PMID: 39091730
Both protein nanoparticle and mRNA vaccines were clinically de-risked during the COVID-19 pandemic. These vaccine modalities have complementary strengths: antigen display on protein nanoparticles can enhance the magnitude, quality, and...
8.
Chappell M, Breda L, Tricoli L, Guerra A, Jarocha D, Castruccio Castracani C, et al.
Blood
. 2024 Jul;
144(15):1633-1645.
PMID: 38949981
α-Thalassemia (AT) is one of the most commonly occurring inherited hematological diseases. However, few treatments are available, and allogeneic bone marrow transplantation is the only available therapeutic option for patients...
9.
Bettini E, Chudnovskiy A, Protti G, Nakadakari-Higa S, Ceglia S, Castano D, et al.
bioRxiv
. 2024 May;
PMID: 38798523
Nucleoside-modified mRNA vaccines elicit protective antibodies through their ability to promote T follicular helper (Tfh) cells. The lipid nanoparticle (LNP) component of mRNA vaccines possesses inherent adjuvant activity. However, to...
10.
Wiehe K, Saunders K, Stalls V, Cain D, Venkatayogi S, Martin Beem J, et al.
Cell Host Microbe
. 2024 Apr;
32(5):693-709.e7.
PMID: 38670093
A major goal of HIV-1 vaccine development is the induction of broadly neutralizing antibodies (bnAbs). Although success has been achieved in initiating bnAb B cell lineages, design of boosting immunogens...